News

Fierce Pharma1d
AACR: Merck's Keytruda prevents head and neck cancer from returning in industry-first win
Ending a 20-year-plus drought, Merck & Co.’s Keytruda demonstrated that its use around surgery can reduce the risk of certain ...
BioSpace1d
Perioperative Keytruda Cuts Risk of Negative Events by Over 25% in Head and Neck Cancer
The FDA is currently reviewing Merck’s sBLA for Keytruda in head and neck cancer, with a target action date of June 23.
Clinical Trials Arena on MSN1d
MSD reports outcomes from Keytruda combination trial for head and neck cancer
MSD has reported outcomes from a Phase III trial of Keytruda (pembrolizumab) for treating head and neck squamous cell ...
Does Merck Stock Have Room For Growth?
The firm reported revenues of $15.53 billion and adjusted earnings per share of $2.22, surpassing consensus predictions of ...
BioPharma Dive1d
New Akeso, Summit data stir debate on PD-1/VEGF drugs
Interim results from a study in China suggest ivonescimab may reduce the risk of death versus Keytruda, but the difference ...
Applied Clinical Trials Online1d
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or ...
Fierce Pharma1d
'Deviated from the core': Akeso CEO tries to reset expectations of bispecific's survival readout amid market tumult
As an unplanned overall survival analysis of ivonescimab’s Keytruda head-to-head trial rocked the PD- (L)1xVEGF world, Akeso ...
Clinical Trials Arena on MSN1d
ALX Oncology’s CD47-blocker and Keytruda combo fails in two Phase II trials
Despite the failures, ALX Oncology remains hopeful about evorpacept and is focusing on combination trials with other ...